middle.news
Race Oncology Advances RC220 Trial and Bolsters Leadership Amid Strong Cash Position
8:37am on Wednesday 23rd of July, 2025 AEST
•
Healthcare
Read Story
Race Oncology Advances RC220 Trial and Bolsters Leadership Amid Strong Cash Position
8:37am on Wednesday 23rd of July, 2025 AEST
Key Points
First patient treated safely with RC220 and RC220 plus doxorubicin in Phase 1 trial
New appointments of Chief Medical Officer Dr Jose Iglesias and VP of Medical Dr Simon Fisher
Cash reserves of $13.67 million at quarter end, supporting activities through 2026
Termination of City of Hope license to reduce costs while retaining freedom to operate
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE